Daclizumab: another option for highly active relapsing‐remitting MS

Daclizumab provides clinicians with a new treatment option for patients with relapsing‐remitting multiple sclerosis. Here the authors consider its benefits compared with other multiple sclerosis drugs and its likely place in therapy.